Actemra - Biological Therapy for Rheumatoid Arthritis (RA)

Print-Icon
Print

Roche's MabThera / Rituxan has recently been approved for the additional indication of RA.
 
«Back | Next»

  • Roche Pharmaceutical - R&D Facility
  • Biopharmaceutical Production at Roche
  • Roche's MabThera - Rituxan
  • Actemra - Therapeutic Monoclonal Antibody
  • Roche's MabThera - Rituxan is an Anti-CD20 Monoclonal Antibody


| 1 | 2 | 3 | 4 | 5 |

Browse More Images - Return to Project




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development